News & Insights

Markets
REGN

Sensei Biotherapeutics Enters Clinical Supply Agreement With Regeneron For Libtayo

January 05, 2023 — 08:23 am EST

Written by RTTNews.com for RTTNews ->

(RTTNews) - Sensei Biotherapeutics, Inc. (SNSE) announced a clinical supply agreement with Regeneron for its anti-PD1 therapy Libtayo. The supply agreement supports the evaluation of SNS-101, a conditionally active VISTA-blocking antibody, in combination with Libtayo in a Phase 1/2 trial in solid tumors. Sensei will sponsor and fund the planned clinical trial and Regeneron will provide Libtayo.

Sensei stated that it is on track to submit an Investigational New Drug application for SNS-101 in or before April 2023 and the trial is expected to commence in 2023.

For More Such Health News, visit rttnews.com.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

Markets
RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source ->

Stocks mentioned

REGN
SNSE

More Related Articles

Info icon

This data feed is not available at this time.

  • •

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.